---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-017637"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:36:43.928203+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B

## Summary
- Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.
- TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.
- 2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).
- Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.
- Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted.

## SEC filing metadata
- accession: 0001140361-26-017637
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/0001140361-26-017637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/ef20071749_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-017637
- JSON: https://secwatch.observer/filing/0001140361-26-017637.json
- Plain text: https://secwatch.observer/filing/0001140361-26-017637.txt

## Key facts
- Earnings Releases
  IONIS PHARMACEUTICALS INC reported first quarter 2026 results: revenue $246 million. Guidance raised.
  - Period: first quarter 2026
  - Revenue: $246 million
  - Guidance: raised
  - Result: reported results
  source text: First Quarter 2026 Summary Financial Results (1): Three months ended March 31, 2026 2025 (amounts in millions) Total revenue $ 246 $ 132 Operating expenses $ 364 $ 278 Operating expenses on a non-GAAP basis $ 321 $ 249 Loss from operations $ (118 ) $ (146 ) Loss from operations on a non-GAAP basis $ (75 ) $ (117 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036126017637/0001140361-26-017637-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.